Project Grant R01EB035529
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This $382,449 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to develop and validate advanced dual-nuclei magnetic resonance imaging (MRI) techniques, including proton-based diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, to non-invasively differentiate between recurrent brain metastasis (RBM) and radiation necrosis (RN) in patients with brain metastases undergoing stereotactic...
- This Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of innovative methods and tools for integrating brain imaging, multi-omics, and behavioral data. The goal is to build predictive models that can accurately identify the key parameters and biomarkers underlying complex psychiatric disorders, advancing the field of precision psychiatry. The award will...
- This $427,625 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to evaluate the use of hyperpolarized 13C magnetic resonance imaging (HPMRI) as a novel diagnostic tool for identifying epileptic tissue. The research aims to: 1) Use a rat model of temporal lobe epilepsy to explore the ability of [1-13C]pyruvate HPMRI to...
- This Project Grant award, totaling $1,491,482, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The project aims to investigate the neurobiological correlates of increased extracellular water volume (free water) observed in schizophrenia patients, particularly during early phases of the disease. The research will leverage a validated animal model (GCLM knockout mice) to test the relationship between oxidative stress,...
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286) to Vanderbilt University Medical Center aims to develop a novel platform for generating partially synthetic chemical exchange saturation transfer (CEST) MRI data to train machine learning models. The $421,632 award, effective August 15, 2025 through April 30, 2029, supports research to address challenges in CEST imaging for detecting and diagnosing glioma, a significant health concern. The...
- This $194,022 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research led by the Massachusetts General Hospital (MGH) to develop advanced deep learning models for predicting therapeutic response in cancer patients with brain metastases. The grant will fund the candidate, an oncologist at MGH, to build upon his expertise in...
- This $233,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research at The Washington University to investigate the potential of hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and ultra-short echo time magnetization transfer (UTE-MT) imaging to non-invasively study the role of lactate metabolism and...
- HYQ Research Solutions, LLC was awarded a $998,104 Cooperative Agreement from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program to develop high dielectric constant materials for accelerating 1.5T magnetic resonance imaging. The two-year award will support the company's efforts to increase MRI signal-to-noise ratio by over 50% and cut scan times in half through incorporating high dielectric constant materials into clinical imaging coils. This novel...
- This Cooperative Agreement award, valued at $700,067.00, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) federal grant program. The primary goal of this project is to develop and validate a new magnetic resonance-based multimodal imaging technology that can simultaneously acquire a large set of molecular and tissue property biomarkers...
MODEL SELECTION FOR MAGNETIC RESONANCE SPECTROSCOPY - PROJECT SUMMARY/ABSTRACT IN-VIVO PROTON MAGNETIC RESONANCE SPECTROSCOPY (1H-MRS) CAN NON-INVASIVELY MEASURE LEVELS OF MORE THAN 20 BIOCHEMICALS IN THE HUMAN BRAIN. WITH ITS ABILITY TO DETECT SURROGATE MARKERS OF NEURONAL HEALTH AND CELL PROLIFERATION, NEUROTRANSMITTERS, ANTIOXIDANTS, TUMOR MARKERS AND OTHERS, 1H-MRS PROVIDES A UNIQUE WINDOW ONTO METABOLIC CHANGES IN HEALTH AND DISEASE. IT THEREFORE HOLDS GREAT POTENTIAL FOR CLINICAL RESEARCH, DIAGNOSIS, AND TREATMENT RESPONSE MONITORING. CLINICAL TRANSLATION OF MRS HAS BEEN CURBED BY THE WIDE RANGE OF AVAILABLE TECHNICAL METHODS FOR DATA ACQUISITION AND ANALYSIS. THESE HAVE OFTEN PRODUCED INCONSISTENT RESULTS. RECENT RESEARCH HAS PARTICULARLY RECOGNIZED THAT METABOLITE LEVEL ESTIMATES DEPEND STRONGLY ON THE WAY THAT THE MEASURED DATA ARE MODELED. TRADITIONAL 1H-MRS ANALYSIS PROCEDURES DO NOT CAPTURE THIS UNCERTAINTY, AND THERE ARE CURRENTLY NO METHODS TO DETERMINE WHETHER ONE MODEL IS PREFERABLE OVER ANOTHER. THE CORE THEME OF THIS PROJECT IS A PARADIGM SHIFT: FITTING THE MEASURED DATA WITH A SET OF MULTIPLE CANDIDATE MODELS WILL REPLACE TRADITIONAL SINGLE-MODEL ANALYSIS. A MULTIVERSE ANALYSIS FRAMEWORK WILL THEN CAPTURE AND QUANTIFY THE VARIABILITY ACROSS THE CANDIDATE MODELS, PARTICULARLY FOCUSING ON CURRENTLY EXISTING MRS SOFTWARE. MODEL SELECTION TOOLS, IN CONTRAST, WILL USE STATISTICAL INFORMATION CRITERIA TO ACTIVELY DISCRIMINATE WHICH MODELS ARE THE MOST SUITABLE FOR A GIVEN DATASET. THESE TWIN STRATEGIES (SIMULTANEOUS CONSIDERATION OF MULTIPLE CANDIDATE MODELS AND DATA-DRIVEN IDENTIFICATION OF THE 'BEST' MODELS) ARE COMPLEMENTARY AND PROVIDE PRACTICAL TOOLS TO BOOST THE ACCURACY AND PRECISION OF METABOLITE MEASUREMENT. CLINICAL AND RESEARCH UTILITY OF THE NEW STRATEGIES ARE FURTHER AMPLIFIED BY INTERFACING THEM WITH STOCHASTIC MARKOV CHAIN MONTE CARLO SAMPLING. THESE METHODS ALLOW MODEL PARAMETER DISTRIBUTIONS TO BE CHARACTERIZED MORE ACCURATELY, PROVIDING ALTERNATIVE MEANS OF UNCERTAINTY ESTIMATION THAT ELIMINATE MANY WEAKNESSES OF TRADITIONAL CRAMER-RAO LOWER BOUNDS (CRLB). THE PROJECT WILL FURTHER DEMONSTRATE THAT THESE NEW METHODS IMPROVE THE ACCURACY AND PRECISION OF NON-INVASIVE MEASUREMENT OF 2-HYDROXYGLUTARATE (2-HG), A HIGHLY SPECIFIC ONCOMETABOLITE THAT PLAYS A PIVOTAL ROLE IN IDH- MUTATED LOW-GRADE GLIOMA. IN SUMMARY, THIS PROJECT PROPOSES SEVERAL NOVEL DATA ANALYSIS STRATEGIES FOR IN-VIVO 1H-MRS THAT ADDRESS THE CHALLENGE OF ANALYTIC VARIABILITY ASSOCIATED WITH THE CHOICE OF MODELING APPROACH. ALL DEVELOPED SOFTWARE CODE WILL BE MADE AVAILABLE TO THE COMMUNITY THROUGH OUR WELL-ESTABLISHED OPEN-SOURCE SOFTWARE 'OSPREY'.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $558.1k | 5/7/25 | ||
| Not listed | $574.3k | 7/26/24 | ||
| Not listed | $574.3k | 7/26/24 |